AI is changing the way pharma companies approach pricing, market access, and HTA submissions. Are you prepared to make the most of these new opportunities?
In our AI for Pharma Market Access course with Dr Stefan Walzer, participants learn how to apply AI in a practical and efficient way to support decision-making, engage payers, and improve value communication.
Take this 2-minute quiz to check your knowledge and see where AI can make an impact:
1) Where can AI add value in the pharma product lifecycle?
A) Only in clinical development
B) Primarily in commercial marketing
C) Across the entire lifecycle, from R&D to market access and beyond
D) Only during post-approval safety monitoring
C) Across the entire lifecycle, from R&D to market access and beyond
AI supports activities throughout R&D, regulatory, pricing, HTA, reimbursement, and post-launch.
2) Which regulation is critical for data protection also when using AI in European pharma activities?
A) FDA Act
B) HIPAA
C) GDPR
D) EU Pharma Code
C) GDPR
GDPR governs data privacy and is hence also essential for compliant AI use.
3) How can AI enhance payer negotiation preparation?
A) Predicting clinical trial success
B) Simulating payer objections and responses
C) Manufacturing virtual trial drugs faster
D) Lowering drug production costs directly
B) Simulating payer objections and responses
AI tools can simulate negotiation scenarios, anticipate objections, and support objection handling strategies.
4) Which of these is NOT a major risk of unregulated AI in pharma?
A) Data bias
B) Faster processing
C) Privacy breaches
D) "Black-box" unpredictability
B) Faster processing
Faster processing is a benefit — the real potential risks are bias, privacy issues, and lack of explainability.
5) Which organisation has already published AI-related healthcare guidelines?
A) EMA
B) NICE
C) IQWiG
D) All of the above
A) EMA and B) NICE
EMA and NICE have each issued (preliminary) guidelines for AI evaluation use.
6) What must health economic models, built using AI, prioritise to gain payer acceptance?
A) Visual appeal of graphs
B) Predictive speed over accuracy
C) Explainability and modelling guideline compliance
D) Outsourcing to external vendors
C) Explainability and modelling guideline compliance
Health technology assessment (HTA) bodies demand explainability, compliance, and credible methods.
7) What are the three pillars of the Pharma AI Readiness Index according to CB Insights?
A) Talent, Execution, Innovation
B) Sales Growth, Clinical Results, Digital Spending
C) Research Volume, Market Share, Patient Access
D) Payer Satisfaction, Therapy Cost, Brand Visibility
A) Talent, Execution, Innovation
Talent, Execution, and Innovation measure a company’s readiness to adopt AI successfully.
8) What is a key expectation when using AI-generated content for HTA dossiers?
A) Creative storytelling and brand messaging
B) Full human oversight and validation
C) Automated decision-making without checks
D) Maximising speed over quality
B) Full human oversight and validation
HTA agencies require human validation to ensure compliance, accuracy, and ethical standards.
🎯 How did you score?
| Score % | Title | |
|---|---|---|
| 0–40% | Beginner | You’re just starting your AI journey — a great world can open up for you! |
| 41–70% | AI Explorer | You’re getting familiar! Next step is building your confidence and skills! |
| 71–100% | Market Access Transformer | You’re future-ready! This is a fast moving space, so keep track of new and advanced applications by enrolling! |
Ready to take the next step? Join peers from leading pharma companies at our expert-led course:
🎓 If you want to:
- Master the essentials of AI in pharma market access: Understand key terminology, explore the transformative impact of AI, and tackle industry-specific challenges.
- Integrate AI-driven tools with confidence: Learn how to seamlessly incorporate AI into market access processes to boost efficiency and achieve superior outcomes.
- Discover the best AI systems for your needs: Get an overview of available AI technologies, along with their pros and cons, tailored to pharma market access applications.
- Gain hands-on experience with AI in action: Participate in practical exercises using AI-driven tools for market access planning, systematic literature reviews, dossier writing, and payer negotiations.
(Features a real-life prostate cancer case study to simulate and solve real-world challenges across the market access lifecycle.) - Learn from your peers in pharma market access: Benefit from peer insights as they will share their challenges, experiences, and innovative solutions.
👉 Attend Dr Stefan Walzer’s highly praised 2-day course:
The AI for Pharma Market Access Course
With Dr Stefan Walzer
